Clarfeld Financial Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Clarfeld Financial Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$6K	Buy	+17	New	+$6.22K	0.01%	302

Other funds holding REGN

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Clarfeld Financial Advisors's REGN Position: Q4 2018 in Review

Clarfeld Financial Advisors opened a new position in Regeneron Pharmaceuticals (REGN) in Q4 2018: 17 shares worth $6K. The stake represents 0.01% of the portfolio and ranks #302 among its holdings.

671 funds tracked by Wall St. Rank hold REGN as of Q4 2018.

Clarfeld Financial Advisors held 17 shares of Regeneron Pharmaceuticals worth $6K as of Q4 2018.
Regeneron Pharmaceuticals was a new Clarfeld Financial Advisors position in Q4 2018.
Regeneron Pharmaceuticals made up 0.01% of Clarfeld Financial Advisors's portfolio in Q4 2018, its #302 holding.
671 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2018.

Based on Clarfeld Financial Advisors's 13F filing for Q4 2018, filed 15 Feb 2019.